Alliance Pharma plc (LON:APH - Get Free Report) shares reached a new 52-week high on Tuesday . The company traded as high as GBX 61.60 ($0.77) and last traded at GBX 61.20 ($0.76), with a volume of 5385101 shares trading hands. The stock had previously closed at GBX 61.20 ($0.76).
Alliance Pharma Stock Performance
The firm has a market capitalization of £330.83 million, a price-to-earnings ratio of -1,020.00, a P/E/G ratio of 1.04 and a beta of 0.67. The company has a 50-day moving average price of GBX 49.65 and a 200-day moving average price of GBX 43.91. The company has a quick ratio of 1.42, a current ratio of 2.93 and a debt-to-equity ratio of 47.46.
About Alliance Pharma
(
Get Free Report)
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alliance Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alliance Pharma wasn't on the list.
While Alliance Pharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
